EGFR and non-small cell lung carcinoma: A total of 127 patients with EGFR‐mutant NSCLC progressed on prior EGFR‐TKI and received salvage treatment—ABCP arm: n = 35; immune oncology drugs (IO) arm: n = 53; pemetrexed and carboplatin (PemC) arm: n = 39—were analyzed for clinical efficacy (Table 1S, Figure 1A).